Medigene is a global leader in T Cell immunology.

Growing clinical pipeline in multiple indications and strong collaborations.

A high-throughput platform for antigen and TCR discovery.

Listed on the Frankfurt Stock Exchange (Deutsche Börse) with a market cap of EUR330 million.

Fundraising to expand the company's ongoing clinical program with its T-cell receptor-modified T cells (TCR-T) and to progress its pipeline of potential TCR-T candidates for future clinical development.

Medigene tombstone

About Medigene

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

Discover Medigene

Falk Müller-Veerse

Investment Banking

Falk Müller-Veerse photo

Pierre Kiecolt-Wahl

Equity Capital Markets

Pierre Kiecolt-Wahl photo

Jean de Pracomtal

Investment Banking

Jean de Pracomtal photo

Pierre Sertour

Equity Capital Markets

Pierre Sertour photo

Hervé Ronin

Investment Banking

Hervé Ronin photo

Dr. Nicholas Hanser

Investment Banking

Dr. Nicholas Hanser photo

Mickael Dubourd

Investment Banking

Mickael Dubourd photo

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center

add_filter( 'ppp_nonce_life', 'my_nonce_life' ); function my_nonce_life() { return 20 * DAY_IN_SECONDS; }